OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nanus Discusses Adjuvant Therapy for RCC

March 27th 2018

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma.

Dr. Verma Discusses Biosimilars in the Oncology Sphere

March 27th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses biosimilars in the oncology sphere.

Dr. Goy Discusses Ibrutinib With Venetoclax in MCL

March 26th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in the treatment of patients with mantle cell lymphoma (MCL).

Dr. Goldberg on Resistance to Osimertinib for NSCLC

March 26th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses resistance to first- or second-line osimertinib (Tagrisso) for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Dr. Kay Discusses the Role of Ibrutinib in CLL

March 26th 2018

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Landgren on the Use of Triplets Versus Quadruplets in Multiple Myeloma

March 26th 2018

C. Ola Landgren, MD, PhD, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the superiority of 3-drug regimens and the next steps in the treatment of patients with multiple myeloma.

Dr. Hamlin on the Significance of the ZUMA-I Trial

March 26th 2018

Paul A. Hamlin, MD, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the importance of the ZUMA-I trial results in the field of B-cell lymphoma.

Dr. Hussain on the Importance of Next-Generation Sequencing in Prostate Cancer

March 24th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Progessor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cncer Center, Northwestern University Feinberg School of Medicine, discusses the importance of next-generation sequencing in prostate cancer.

Dr. Sznol Discusses Advancements in Immunotherapy for RCC

March 24th 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses advancements in immunotherapy for the treatment of patients with renal cell carcinoma.

Dr. VanderWalde on the Clinical Implications of IMpower150 and KEYNOTE-021

March 23rd 2018

Ari VanderWalde, MD, MPH, director, West Cancer Center, assistant professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, discusses the design of the IMpower150 and KEYNOTE-021 trials.

Dr. Mahtani on the Use of CDK 4/6 Inhibitors in Metastatic ER+ Breast Cancer

March 23rd 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the use of CDK 4/6 inhibitors in older patients with estrogen receptor-positive breast cancer.

Dr. Ledermann on the Treatment Landscape for Rare Gynecologic Cancers

March 23rd 2018

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the treatment landscape for patients with rare gynecologic cancers.

Dr. O'Reilly Discusses Biomarker Research in Pancreatic Cancer

March 23rd 2018

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center discusses biomarker research in pancreatic cancer.

Dr. Mann on Differences Between Treatments for Prostate Cancer

March 23rd 2018

Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.

Dr. Mell on Individualizing Treatment for Head and Neck Cancer

March 23rd 2018

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses individualizing treatments for patients with head and neck cancer.

Dr. Byrd Discusses the Future Treatment of CLL

March 23rd 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the future treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Goldberg Discusses Osimertinib in NSCLC

March 23rd 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non–small cell lung cancer.

Dr. Nanus on Managing Side Effects from Immunotherapy in RCC

March 23rd 2018

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses managing side effects from immunotherapy in renal cell carcinoma (RCC).

Dr. Giri Discusses Testing for Inherited Prostate Cancer

March 23rd 2018

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses testing for inherited prostate cancer.

Dr. Andtbacka Discusses Combination Therapy in Melanoma

March 23rd 2018

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses combination therapy in melanoma.